TY  - JOUR
AU  - Heymach, John V
AU  - Popat, Sanjay
AU  - Smit, Egbert F
AU  - Christopoulos, Petros
AU  - Planchard, David
AU  - Yoshida, Tatsuya
AU  - Zugazagoitia, Jon
AU  - Yu, Yan
AU  - Wilding, Birgit
TI  - The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review.
JO  - Expert review of anticancer therapy
VL  - nn
SN  - 1473-7140
CY  - Abingdon, Oxon
PB  - Taylor & Francis
M1  - DKFZ-2026-00290
SP  - nn
PY  - 2026
N1  - #NCTZFB9# / epub
AB  - HER2 is mutated in 2-4
KW  - Zongertinib (Other)
KW  - human epidermal growth factor receptor 2 (Other)
KW  - non-small cell lung cancer (Other)
KW  - targeted therapy (Other)
KW  - tyrosine kinase inhibitor (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41640088
DO  - DOI:10.1080/14737140.2026.2623059
UR  - https://inrepo02.dkfz.de/record/309658
ER  -